📊 BGMSP Key Takeaways
Investment Thesis
Bio Green Med Solution is a pre-revenue pharmaceutical company burning significant cash with minimal commercial traction. With only $81K in revenue against $7.3M in operating losses and negative free cash flow of $4.7M, the company is consuming its cash reserves at an unsustainable rate. At current burn rates, the $3.8M cash position provides less than 10 months of runway.
BGMSP Strengths
- Minimal debt burden with Debt/Equity ratio of 0.00x
- Adequate liquidity ratios (Current Ratio 6.43x, Quick Ratio 5.07x) in the near term
- Total assets of $8.2M provide some balance sheet cushion
BGMSP Risks
- Critically low revenue of $81K with operating losses of $7.3M indicating failed commercialization or product-market fit
- Negative free cash flow of $4.7M annually will deplete $3.8M cash reserves within 10 months without additional funding
- Extreme profitability deficits: Operating Margin of -9067.9% and Net Margin of -2946.9% indicate fundamental business model failure
- Zero insider filings in last 90 days suggests lack of confidence from management
- No clear path to profitability with massive operating losses relative to minimal revenue
Key Metrics to Watch
- Quarterly revenue trends and commercial milestones
- Monthly cash burn rate and remaining runway
- Operating loss trajectory and cost structure improvements
- Cash position and timeline for next funding requirement
BGMSP Financial Metrics
💡 AI Analyst Insight
Strong liquidity with a 6.43x current ratio provides a solid financial cushion.
BGMSP Profitability Ratios
BGMSP vs Healthcare Sector
How Bio Green Med Solution, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
BGMSP Balance Sheet & Liquidity
BGMSP 5-Year Financial Trend
5-Year Trend Summary: Bio Green Med Solution, Inc.'s revenue has grown significantly by 180% over the 5-year period, indicating strong business expansion. The most recent EPS of $-26.75 indicates the company is currently unprofitable.
BGMSP Growth Metrics (YoY)
BGMSP Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $10.0K | -$81.0K | $-1.31 |
| Q2 2025 | $4.0K | -$81.0K | $-0.98 |
| Q1 2025 | $29.0K | -$81.0K | $0.00 |
| Q3 2024 | $10.0K | -$2.0M | N/A |
| Q1 2024 | N/A | -$2.9M | $-2.27 |
| Q3 2023 | N/A | -$4.1M | N/A |
| Q2 2023 | N/A | -$2.9M | $-0.44 |
| Q1 2023 | N/A | -$4.1M | $-0.42 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
BGMSP Capital Allocation
BGMSP SEC Filings
Access official SEC EDGAR filings for Bio Green Med Solution, Inc. (CIK: 0001130166)
📋 Recent SEC Filings
❓ Frequently Asked Questions about BGMSP
What is the AI rating for BGMSP?
Bio Green Med Solution, Inc. (BGMSP) has an AI rating of STRONG SELL with 95% confidence, based on fundamental analysis of SEC EDGAR filings.
What are BGMSP's key strengths?
Minimal debt burden with Debt/Equity ratio of 0.00x. Adequate liquidity ratios (Current Ratio 6.43x, Quick Ratio 5.07x) in the near term.
What are the risks of investing in BGMSP?
Critically low revenue of $81K with operating losses of $7.3M indicating failed commercialization or product-market fit. Negative free cash flow of $4.7M annually will deplete $3.8M cash reserves within 10 months without additional funding.
What is BGMSP's revenue and growth?
Bio Green Med Solution, Inc. reported revenue of $81.0K.
Does BGMSP pay dividends?
Bio Green Med Solution, Inc. does not currently pay dividends.
Where can I find BGMSP SEC filings?
Official SEC filings for Bio Green Med Solution, Inc. (CIK: 0001130166) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is BGMSP's EPS?
Bio Green Med Solution, Inc. has a diluted EPS of $-2.86.
How is the AI analysis conducted?
Our AI (Claude) analyzes publicly available SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports to evaluate financial health, profitability ratios, balance sheet strength, and growth metrics.